WHO sets the bar for next-gen TB treatments with long-acting injectable guidelines

Tuberculosis remains one of the world's deadliest infectious diseases, and one of its biggest treatment challenges is simple: getting patients to stick with months of daily oral medication. The WHO is now laying the groundwork for a better solution — long-acting injectables (LAIs) — by publishing detailed target regimen profiles (TRPs) that define exactly what any new LAI-based TB regimen must achieve to be worth developing.

The profiles cover two scenarios: TB preventive treatment (ideally delivered in a single injection at one visit) and TB disease treatment (no more than four months, in three or fewer dosing encounters). Both must match or beat current oral regimens in efficacy and safety, require no cold chain, use small injection volumes, and be deliverable at the lowest feasible level of the health system.

Key Takeaways:

• Minimal and optimal requirements are defined for each characteristic, giving developers a clear development target
• Equitable access, transparent pricing, scalability, and patient choice are explicitly built into the framework
• Work on improved oral regimens should continue in parallel for patients who prefer not to receive injections
• The profiles were shaped by trialists, regulators, TB-affected communities, and a multicountry patient preference study

Why it matters: LAIs have already transformed HIV management — and WHO's early-stage guidance could accelerate a similar shift for TB, potentially improving adherence, reducing health system burden, and expanding access globally.